The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of ...

Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient.

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

As a daily pill-taker, I’ve learned that the phrase “Out of sight, out of mind” holds all too true when it comes to staying on top of my medications. A pill case that looks and feels nice ...